Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 23;24(3):248–257. doi: 10.1111/1744-9987.13434

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Comparison of evocalcet and cinacalcet treatment. (A) Comparison of outcomes for evocalcet, cinacalcet, and combination evocalcet/cinacalcet therapy. Time‐course of changes in (B) intact parathyroid hormone, (C) serum‐corrected calcium, (D) serum phosphorus, and (E) intact fibroblast growth factor 23 in patients treated with evocalcet or cinacalcet. Figure adapted from Table 2 and Figure 2a,d,e,f in Fukagawa et al. 45. CI, confidence interval; FGF23, fibroblast growth factor 23; iPTH, intact parathyroid hormone.